Tag

Hepatoblastoma

All articles tagged with #hepatoblastoma

Two Doses of Experimental CAR-T Therapy Erase Liver Cancer in 3-Year-Old
health22 days ago

Two Doses of Experimental CAR-T Therapy Erase Liver Cancer in 3-Year-Old

A three-year-old boy with chemo-resistant hepatoblastoma achieved complete cancer remission after receiving two doses of an experimental CAR-T cell therapy. The treatment, which targets the glypican-3 protein, was administered in an outpatient setting without severe side effects. Published in The New England Journal of Medicine, this single-patient case suggests a potential new avenue for treating solid tumors, which have historically resisted CAR-T therapies.

Experimental CAR-T Therapy Achieves Durable Remission in Child with Metastatic Liver Cancer
health25 days ago

Experimental CAR-T Therapy Achieves Durable Remission in Child with Metastatic Liver Cancer

A 3-year-old boy with advanced hepatoblastoma achieved a complete, cancer-free remission lasting over 12 months after receiving two doses of an experimental CAR-T cell therapy. The treatment, which targets the glypican-3 protein, was administered in an outpatient setting without severe side effects. This single-case success, reported in the New England Journal of Medicine, highlights potential for treating solid tumors, though broader trials are still underway.

Three-Year-Old Achieves Complete Remission of Metastatic Liver Cancer via Experimental CAR T-Cell Therapy
health-and-science28 days ago

Three-Year-Old Achieves Complete Remission of Metastatic Liver Cancer via Experimental CAR T-Cell Therapy

A three-year-old boy with chemotherapy-resistant, metastatic hepatoblastoma achieved complete disease regression after receiving two doses of experimental GPC3-CAR T-cell therapy. Published in The New England Journal of Medicine, the case demonstrates that this immunotherapy can effectively treat solid tumors in an outpatient setting without systemic toxicity. The boy, who had previously undergone surgery and chemotherapy with rapid recurrence, remains disease-free after 12 months. This milestone suggests potential for treating other GPC3-positive solid tumors, though further trials are needed to confirm safety and efficacy across broader populations.